Compare Mesoblast Limited (MESO) vs Workday Inc (WDAY) Price & Performance

MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.

While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.

Workday (WDAY) trades at $186.59, up 1.26% on the day, with a neutral technical signal and key support at $185. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.74. Revenue grew to $8.45B in 2025, and net income margin improved to 12.32%. Recent news includes expansion into the UAE and AI product launches, alongside a 2.5% headcount reduction for strategic realignment.

WDAY presents a mixed outlook: analyst consensus is a Buy with a $202.92 price target, signaling upside potential driven by AI integration and revenue growth. However, risks include execution challenges from restructuring, competitive pressures, and a high P/E ratio of 38.25. Investors should weigh strong fundamentals against near-term volatility and macroeconomic headwinds.